STOCK TITAN

CannaPharmaRX delays Q3 report; revenue falls to $138K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

CannaPharmaRX, Inc. (CPMD) said its Form 10-Q for the quarter ended September 30, 2026, was delayed because it needed more time to obtain and compile required information, a delay it said could not be eliminated without unreasonable effort or expense. It said it will file no later than the fifth calendar day following the prescribed due date.

For the three months ended September 30, 2026, revenue was $137,705 versus $656,606 in 2025, and gross loss was $277,782 versus $373,707. Net income was $645,416 versus a $1,477,811 net loss, primarily reflecting a $1,728,677 non-cash gain on the derivative conversion feature. For the nine months ended September 30, 2026, revenue was $1,041,385 versus $1,223,533, gross loss was $693,142 versus $1,367,918, and net loss was $1,645,647 versus $3,581,863. The lower nine-month net loss primarily reflected lower gross loss and a $1,930,000 other expense in 2025 that did not recur.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointQuarterly net income was $645,416, versus a $1,477,811 net loss in 2025.
  • Moderate pointNine-month net loss narrowed to $1,645,647 from $3,581,863 in 2025.

Negative

  • Moderate pointQuarterly revenue was $137,705, versus $656,606 in 2025.
  • Moderate pointNine-month revenue was $1,041,385, versus $1,223,533 in 2025.
Three-month revenue $137,705 Three months ended September 30, 2026; $656,606 for the comparable 2025 period.
Nine-month revenue $1,041,385 Nine months ended September 30, 2026; $1,223,533 for the comparable 2025 period.
Three-month gross loss $277,782 Three months ended September 30, 2026; $373,707 for the comparable 2025 period.
Nine-month gross loss $693,142 Nine months ended September 30, 2026; $1,367,918 for the comparable 2025 period.
Three-month net income $645,416 Three months ended September 30, 2026, versus a net loss of $1,477,811 in 2025; the change primarily reflected a $1,728,677 non-cash gain on the derivative conversion feature.
Nine-month net loss $1,645,647 Nine months ended September 30, 2026; $3,581,863 for the comparable 2025 period.
derivative conversion feature financial
"gain on the change in fair value of the derivative conversion feature"
fair value financial
"change in fair value of the derivative conversion feature"
Fair value is an estimate of what an asset or company is really worth today, derived from expected future earnings, comparable market prices and other relevant facts—like agreeing a price for a used car after checking mileage, condition and similar listings. Investors use fair value to decide whether a stock looks overpriced or undervalued, which helps guide buy, hold or sell decisions and sets expectations for potential returns and risk.
inventory write-downs financial
"primarily due to lower inventory write-downs"
Inventory write-downs are an accounting move where a company lowers the recorded value of goods it holds because those items are worth less than the price on the books—like a store stamping down the price of damaged, obsolete, or unsellable stock. They cut reported profit and asset value, and can signal weak demand, pricing pressure, or poor inventory management, so investors watch them as a clue to future earnings and cash flow strength.
Rule 12b-25 regulatory
"In accordance with Rule 12b-25"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will CannaPharmaRX (CPMD) file its delayed September 2026 10-Q?

CannaPharmaRX said it will file its Form 10-Q no later than the fifth calendar day following the prescribed due date.

What were CannaPharmaRX (CPMD)'s third-quarter 2026 results?

For the three months ended September 30, 2026, revenue was $137,705, gross loss was $277,782, and net income was $645,416. In the comparable 2025 period, revenue was $656,606, gross loss was $373,707, and net loss was $1,477,811.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

SEC FILE NUMBER - 000-27055

CUSIP NUMBER - 13765D109

 

NOTIFICATION OF LATE FILING

 

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K    
  ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
                 
  For Period Ended: September 30, 2026
         
  ☐ Transition Report on Form 10-K
  ☐ Transition Report on Form 20-F
  ☐ Transition Report on Form 11-K
  ☐ Transition Report on Form 10-Q
     
  For the Transition Period Ended: __________________________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 
PART I - REGISTRANT INFORMATION

 

CannaPharmaRX, Inc.  
Full Name of Registrant  

 

 

 
Former Name if Applicable
 
4439 Township Rd 304  
Address of Principal Executive Office (Street and Number)
 
Mountain View County, Alberta, Canada T0M 0R0  
City, State and Zip Code

 

 

 

   

 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

☒ (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
   
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

(Attach extra Sheets if Needed)

 

The Registrant could not complete the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 due to a delay in obtaining and compiling information required to be included in its Form 10-Q, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Registrant will file its Form 10-Q no later than the fifth calendar day following the prescribed due date.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Constantine Nkafu   (403)   637-0420
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
   
(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☒ No ☐

   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

During the three and nine months ended September 30, 2026, the Company reported revenues of $137,705 and $1,041,385, respectively (2025 – $656,606 and $1,223,533, respectively). The decrease from the prior-year comparable periods was primarily driven by lower cannabis sales volumes.

 

During the three and nine months ended September 30, 2026, the Company reported a gross loss of $277,782 and $693,142, respectively (2025 – $373,707 and $1,367,918, respectively). The decrease from the prior-year comparable periods was primarily due to lower inventory write-downs. Comparative figures have been reclassified to conform to the current period’s presentation.

 

During the three and nine months ended September 30, 2026, the Company reported net income of $645,416 and a net loss of $1,645,647, respectively (2025 – net loss of $1,477,811 and $3,581,863, respectively). The change for the three-month period was primarily due to a non-cash gain of $1,728,677 on the change in fair value of the derivative conversion feature. The decrease in net loss for the nine-month period was primarily due to the lower gross loss and a $1,930,000 other expense recorded in 2025 that did not recur.

 

 

 

 2 

 

 

CannaPharmaRX, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 17, 2026 By: /s/ Oliver Foeste  
    Oliver Foeste  
    Chief Financial Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

Keep reading